Comparative Study of Bronchodilator Effect of Three Brands of Salmeterol, ?in Asthmatic Patients
Trauma Monthly: 12 (2); 153-160 Article Type: Research Article
January 1, 2007
January 1, 2007
H. Comparative Study of Bronchodilator Effect of Three Brands of Salmeterol, ?in Asthmatic Patients,
Online ahead of Print
Aims. Asthma is a common chronic disease with episodic attacks which induces heavy economic burden on the health system, while by considering an effective and cheap therapeutic method, it is possible to reduce the burden. Salmeterol spray is one of the common used drugs in asthmatic patients. There are three brands of this drug in Iran: Iran-manufactured Salmeterol (Salmeterol), India-manufactured (Serobide) and England-manufactured (Serovent), which have different efficacy and cost and have been studied in this survey. Methods. In this randomized clinical trial 30 asthmatic patients with inclusion criteria randomly divide into three groups and each group received one of the brands. A base Spirometery was done for each patient firstly, and then they used 50 mcg of drug in two doses (q12h) for three days. For every patient diurnal pick flow meter, three times a day, and also a final Spirometery in the third day of study was done. To calculate cost-efficacy the Economical Preferability Index was used. Results. All three brands caused increase in lung volume, after three days treatment, while Serovent and Salmeterol led to significant rise (P<0.05). The final cost of Iran-manufactured salmeterol to increase one liter in lung volume was less than Serobide but non-significantly while it was significantly less than Serovent. (P<0.05) Conclusion. In recent studies combination therapy of long-acting inhaled bronchodilators like Salmeterol and inhaled corticosteroids is the most effective therapeutic method to control asthma. Regarding numerous asthmatic patients and heavy burden of import of foreign brands and beside considerable difference between their costs, such these studies are valuable due to efficacy and cost-efficacy of Iran-manufactured drugs.
© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.